Se connecter Inscription gratuite

Panbela Therapeutics Revenu

Quel est le Revenu de Panbela Therapeutics?

Le Revenu de Panbela Therapeutics Inc. est -$23.51

Quelle est la définition de Revenu?

Le résultat net disponible pour les actionnaires ordinaires correspond au résultat net moins les dividendes privilégiés versés.

Net income available to common shareholders are the profits remaining after the company pays all of its suppliers, employees, service providers, creditors, and preferred shareholders. In other words, this is revenue less all expenses and preferred dividends. The number measures common shareholders' claim on the company's cash flows.

Revenu des entreprises dans Health Care secteur sur NASDAQ par rapport à Panbela Therapeutics

Que fait Panbela Therapeutics?

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.

Entreprises avec revenu similaire à Panbela Therapeutics